// App-Quantinova.ai

441 : Identification of characteristics associated with long-term survival in patients with metastatic urothelial carcinoma (mUC) who received durvalumab (D) with or without tremelimumab (T) in clinical studies.

Researchers

Presenter

  • Marie Alt

Principal Investigators

  • Carlos Stecca

  • Shaum Kabadi

  • Benga Kazeem

  • Srikala S. Sridhar

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • AstraZeneca, Gaithersburg, MD

  • Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada

Locations

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Ticilimumab

  • Durvalumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved